DNA damage repair (DDR) enzymes, including Ataxia telangiectasia and Rad3-related protein serine/threonine kinase (ATR), are crucial for maintaining stability in cells. Rakovina’s presentation will highlight the Company’s ATR inhibitor program developed in collaboration with Variational AI and their Enki™ generative AI platform. “The data to be presented at AACR-NCI-EORTC reflects the continued progress of our AI-driven drug discovery pipeline and the importance of our collaboration with Variational AI,” said Prof. Mads Daugaard, President and Chief Scientific Officer of Rakovina Therapeutics. For more information, please visit: https://www.aacr.org/meeting/aacr-nci-eortc-international-conference-on-molecular-targets-and-cancer-therapeutics-2025/About Rakovina Therapeutics Inc.Rakovina Therapeutics is a biopharmaceutical research company focused on the development of innovative cancer treatments. Notice Regarding Rakovina Therapeutics Forward-Looking Statements:This release includes forward-looking statements regarding the company and its respective business, which may include, but is not limited to, statements with respect to the proposed business plan of the company and other statements.